Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q1 2016 call → NOWe need to answer YES or NO based on the transcript. The question asks: does management explain where the company's business is going by narrating what its counterparties are themselves doing and scaling? That is, does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to check the transcript. The company is Curis, Inc. They have programs: CUDC-907, CA170, and Erivedge (commercialized by Genentech/Roche). The call discusses their own clinical trials, their own progress. They mention Erivedge is commercialized by Genentech and Roche. They note that Roche has initiated two clinical studies with Erivedge outside of BCC: one in myelofibrosis with ruxolitinib, and one in IPF with pirfenidone. That is about their partner's activities. But does management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific counterparties? The question is about whether the company's own coming volume is presented as a consequence of those parties' own trajectories. For Erivedge, they receive royalties from Genentech/Roche sales. But the call does not discuss scaling of Erivedge sales or that the company's future is driven by Genentech's expansion. They just mention that Roche has initiated two clinical studies. That is not about scaling of sales or volume. The main forward account is about their own clinical trials for CUDC-907 and CA170. They are developing their own drugs. They are not narrating counterparties' trajectories as the driver of their business. The mention of Roche's studies is a brief note, not a substantial part of the forward account. Also, the company is not already inside that growth in the sense of supplying or serving those counterparties with volume. They are a biotech with royalties. The question is about a company whose forward story is a report on somebody else's expansion. Here, the company's story is about its own clinical development. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.